News for Cosmo Pharmaceuticals N.V. (CMOPF)

Published at

May 30, 2025 4:30 PM

by gurufocus.com

positive

positive

Voting Results of Cosmo's 2025 AGM | CMOPF Stock News

Cosmo Pharmaceuticals (CMOPF) shareholders approved all items at the 2025 AGM. A dividend of â‚¬2.05 per share was approved, representing a 2.5% increas

COPN.SW CMOPF 0RGI.L

Read more →
Published at

Apr 29, 2025 4:31 PM

by gurufocus.com

positive

positive

Cosmo Pharmaceuticals Confirms Financial Guidance Following CHMP Opinion on Winlevi(R) | CMOPF Stock News

Cosmo Pharmaceuticals maintains 2025 financial guidance despite a negative CHMP opinion on Winlevi®. The company is preparing a re-examination submission f

COPN.SW CMOPF 0RGI.L

Read more →
Published at

Apr 29, 2025 8:45 AM

by gurufocus.com

mixed

mixed

Cosmo Receives Negative CHMP Opinion on Winlevi(R) (clascoterone Cream 1%) in Europe and Will Appeal the Decision | CMOPF Stock News

Cosmo Pharmaceuticals (SIX: COPN) plans to appeal a negative CHMP opinion on Winlevi® (clascoterone cream 1%) for Europe's market. The CHMP's concerns

COPN.SW 0RGI.L CMOPF

Read more →
Published at

Apr 29, 2025 8:15 AM

by gurufocus.com

positive

positive

Cosmo Publishes Agenda of AGM 2025 | CMOPF Stock News

Cosmo Pharmaceuticals (CMOPF) has scheduled its Annual General Meeting (AGM) for May 30, 2025, in Amsterdam. The agenda includes the approval of the 202

COPN.SW CMOPF 0RGI.L

Read more →
Published at

Mar 7, 2025 8:00 PM

by gurufocus.com

positive

positive

Cosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and Strategic Challenges

Release Date: March 06, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Cosmo Pharmaceu

CMOPF

Read more →
Published at

Feb 10, 2025 9:47 AM

by seekingalpha.com

positive

positive

Cosmo, Glenmark secure UK MHRA approval of Winlevi for treatment of acne

Cosmo Pharmaceuticals N.V. (CMOPF) Monday said that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi in the United Kingdom.

COPN.SW CMOPF 0RGI.L

Read more →
Published at

Oct 9, 2024 9:10 PM

by gurufocus.com

positive

positive

Cosmo Pharmaceuticals NV (CMOPF) (H1 2024) Earnings Call Highlights: Revenue Surge and Strategic Partnerships Propel Growth

Revenue: EUR136.2 million, up from EUR43.7 million last year.Healthtech Revenue: Increased from EUR6.4 million to EUR97.5 million, driven by a EUR100 million u

CMOPF

Read more →
Published at

Jun 6, 2024 7:42 AM

by marketscreener.com

neutral

neutral

Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Proposed Amendments to the Renumeration Policy

DRAFT REMUNERATION POLICY COSMO Pharmaceuticals N.V. REMUNERATION POLICY 1. Introduction This...

COPN.SW CMOPF 0RGI.L

Read more →
Published at

Jun 6, 2024 7:42 AM

by marketscreener.com

neutral

neutral

Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Explanatory Notes

EXPLANATORY NOTES TO THE AGENDA OF THE EXTRAORDINARY GENERAL MEETING OF COSMO PHARMACEUTICALS N.V. ON FRIDAY 5 JULY 2024. Item 1: Opening of the EGM. ...

COPN.SW CMOPF 0RGI.L

Read more →
Published at

Jun 6, 2024 7:42 AM

by marketscreener.com

positive

positive

Cosmo Pharmaceuticals N : EGM – 5 July 2024 – Notification of number of shares as of 6 June 2024

NOTIFICATION OF NUMBER OF OUTSTANDING SHARES AND VOTING RIGHTS As of June 6, 2024, COSMO Pharmaceuticals N.V. has issued 17,543,522 ordinary shares, of which...

COPN.SW CMOPF 0RGI.L

Read more →
Published at

Jun 1, 2024 12:10 AM

by marketscreener.com

positive

positive

Cosmo Reports Excellent Final Full Year 2023 Financial Results - Increases Operating Profit Guidance for 2024 - Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024

Cosmo Pharmaceuticals N.V. today announced its final audited results for the financial year 2023. Financial highlights As previously announced when publishing preliminary...

COPN.SW CMOPF 0RGI.L

Read more →
Published at

May 27, 2024 1:04 PM

by gurufocus.com

positive

positive

Cosmo Pharmaceuticals NV's Dividend Analysis

Exploring the Dividend Performance and Sustainability of Cosmo Pharmaceuticals NV (CMOPF) Cosmo Pharmaceuticals NV (CMOPF) recently announced a dividend of $2 p

CMOPF

Read more →
Published at

May 24, 2024 11:40 PM

by marketscreener.com

neutral

neutral

Cosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General Meeting

Cosmo Pharmaceuticals N.V. today announced that its shareholders approved all agenda items at today's annual general meeting of shareholders. A total of 7,417,916 ordinary shares in...

COPN.SW CMOPF 0RGI.L

Read more →
Published at

Apr 29, 2024 9:09 PM

by marketscreener.com

positive

positive

Cosmo Pharmaceuticals N : has received approval of an extension in respect of the publication and the filing of its annual report 2023

Dublin, Ireland - 29 April 2024: Cosmo Pharmaceuticals N.V. today announced that the company has been granted extension until 31 May 2024 to publish its 2023 annual report and to file such...

COPN.SW CMOPF 2M6.DE 0RGI.L

Read more →
Published at

Apr 25, 2024 7:35 AM

by marketscreener.com

mixed

mixed

Cosmo Announces Leadership Changes

Cosmo Pharmaceuticals N.V. today announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual...

JNJ DJNJ3.BA DJNJ2.BA COPN.SW CMOPF 0RGI.L

Read more →
Published at

Apr 12, 2024 7:20 AM

by marketscreener.com

mixed

mixed

Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care -April 12, 2024 at 01:20 am EDT

Cosmo Pharmaceuticals N.V. announces that Medtronic plc , a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence for...

MDTN.MX MDT.BA MDT 2M6.DE 0Y6X.L COPN.SW CMOPF 0RGI.L

Read more →
Published at

Mar 21, 2024 6:01 AM

by gurufocus.com

neutral

neutral

Full Year 2023 Cosmo Pharmaceuticals NV Earnings Call Transcript

Mar 20, 2024 / 10:00AM GMTAlessandro Della Cha - Cosmo Pharmaceuticals N.V. - CEO & Executive Director Preliminary unaudited full-year 2023 results. Just a litt

COPN.SW CMOPF 0RGI.L

Read more →
Published at

Mar 20, 2024 7:34 AM

by marketscreener.com

positive

positive

Cosmo Pharmaceuticals N : reports excellent preliminary unaudited Full Year 2023 core financial results – Record guidance for 2024 – Doubles dividend to € 2.00 per share -March 20, 2024 at 02:34 am ED

Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval of GI Genius new enhanced operating system. New GI drug development...

COPN.SW CMOPF 2M6.DE 1U1.DE 0RGI.L

Read more →
Published at

Aug 25, 2023 3:54 AM

by prnewswire.com

mixed

mixed

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced

/PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached...

TRSBF 1530.HK CMOPF

Read more →
Published at

Jun 22, 2023 7:17 AM

by marketscreener.com

positive

positive

Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea

Cosmo Pharmaceuticals N.V. / Key word(s): Agreement Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea 22.06.2023 / 06:15 GMT/BST Dublin, Ireland & Seoul, Korea – 22 ...

COPN.SW CMOPF 2M6.DE 0RGI.L 004310.KS

Read more →